This ‘living drug’ could change the course of autoimmune disease
If given the green light by the FDA, a CAR T cell therapy from Kyverna Therapeutics would be the first approved treatment for stiff person syndrome.
If given the green light by the FDA, a CAR T cell therapy from Kyverna Therapeutics would be the first approved treatment for stiff person syndrome.
What's Your Reaction?
SIN
ScienceX Information Network (SIN) | ScienceX Innovations
